SLC44A2 and central nervous system cancer: Pan-cancer analysis revealed that lower SLC44A2 expression was also associated with poorer survival in several other cancers, including clear cell carcinoma of the kidney (KIRC), glioma (GBMLGG), head and neck squamous cell carcinoma (HNSC), and skin cutaneous melanoma (SKCM).